Immune response of hepatitis B vaccine among persons with diabetes: A systematic review of the literature

Diabetes Care

Volumn 35, Issue 12, 2012, Pages 2690-2697

  Schillie, Sarah F ^a   Spradling, Philip R ^a   Murphy, Trudy V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; THYMOPENTIN;

ANTIBODY RESPONSE; ANTIBODY TITER; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; HEMODIALYSIS; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION PREVENTION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; RECOMMENDED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW; VACCINATION;

DIABETES MELLITUS; HEPATITIS B VACCINES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84869786901     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0312     Document Type: Review

References (57)

1. Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:1709-1711
2. André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989;87(3A):14S-20S
3. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986;13(Suppl A):39-45
4. Mast, EE, Weinbaum CM, Fiore AE, et al.; Advisory Committee on Immunization Practices (ACIP)Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1-33; quiz CE1-4.
5. Mast EE, Margolis HS, Fiore AE, et al.; Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54(RR-16):1-31
6. Halsey NA, Moulton LH, O'Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999;103:1243-1247 (Pubitemid 29258800)
7. Clemens R, Sänger R, Kruppenbacher J, et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine 1997;15:349-352 (Pubitemid 27156153)
8. Hussain Z, Ali SS, Husain SA, Raish M, Sharma DR, Kar P. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India. World J Gastroenterol 2005;11:7165-7168 (Pubitemid 43154013)
9. Honorati MC, Mariani E, Dolzani P, Facchini A. Biological parameters influencing the immunological response to plasma derived and recombinant hepatitis B vaccines. Ann Ist Super Sanita 1996;32:369-374 (Pubitemid 27062124)
10. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 2004;20:1053-1062 (Pubitemid 39657938)
11. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1-8 (Pubitemid 28289941)
12. de Rave S, Heijtink RA, Bakker-Bendik M, Boot J, Schalm SW. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994;12:532-534 (Pubitemid 24122861)
13. Douvin C, Simon D, Charles MA, et al. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabetes Care 1997;20:148-151 (Pubitemid 27051551)
14. Bouter KP, Diepersloot RJ, Wismans PJ, et al. Humoral immune response to a yeast-derived hepatitis B vaccine in patients with type 1 diabetes mellitus. Diabet Med 1992;9:66-69
15. Historic dates and events related to vaccines and immunization. Available from: http://www.immunize.org/timeline/. Accessed 5 January 2012
16. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis 1992;12:282-308
17. Ahishali E, Boztas G, Akyuz F, et al. Response to hepatitis B vaccination in patients with celiac disease. Dig Dis Sci 2008;53:2156-2159
18. Chow KM, Law MC, Leung CB, Szeto CC, Li PK. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract 2006;103:c89-c93 (Pubitemid 43952607)
19. Eldesoky A, et al. Protective immunity after hepatitis B vaccination. Arab J Gastroenterol 2009;10:68-71
20. Elwell RJ, Neumann M, Bailie GR. Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: a retrospective cohort study. Pharmacotherapy 2003;23:1558-1563 (Pubitemid 37485308)
21. Halota W, Muszyńska M, Pawłowska M. Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes. Med Sci Monit 2002;8: CR516-CR519 (Pubitemid 34826774)
22. Kramer ES, Hofmann C, Smith PG, Shiffman ML, Sterling RK. Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis. Dig Dis Sci 2009;54:2016-2025
23. Marseglia G, Alibrandi A, d'Annunzio G, et al. Long term persistence of anti-HBs protective levels in young patients with type 1 diabetes after recombinant hepatitis B vaccine. Vaccine 2000;19:680-683
24. Morais EO, Resende MR, Oliveira AM, et al. Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up. Aliment Pharmacol Ther 2007;25:849-855 (Pubitemid 46434916)
25. Pascasio JM, Aoufi S, Gash A, et al. Response to a vaccination schedule with 4 doses of 40 microg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation. Transplant Proc 2008; 40:2943-2945
26. Pozzilli P, Arduini P, Visalli N, et al. Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 1987;30:817-819 (Pubitemid 17163009)
27. Somboonsilp W, Eiam-Ong S, Tungsanga K, Tirawatanapong T. Immune response of intradermal hepatitis B vaccination at lower dose versus intramuscular vaccination at double standard dose in predialytic chronic renal failure patients. J Med Assoc Thai 2003;86:1122-1127 (Pubitemid 38313454)
28. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou S, Thomoglou V, Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007;68:228-234 (Pubitemid 47527443)
29. Wismans PJ, van Hattum J, de Gast GC, et al. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol 1991;35:216-222
30. Arslanoǧlu I, Cetin B, Isgüven P, Karavus M. Anti-HBs response to standard hepatitis B vaccination in children and adolescents with diabetesmellitus. J Pediatr Endocrinol Metab 2002;15:389-395 (Pubitemid 34704804)
31. Chin AI. Hepatitis B virus vaccine response in hemodialysis: baseline patient characteristics. Hemodial Int 2003;7:296-303
32. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003;42:1184-1192 (Pubitemid 37486762)
33. Eardley KS, Jones HE, Osman H, Smith SA. Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: a single-centre experience. Nephrol Dial Transplant 2002;17:1982-1987 (Pubitemid 35277098)
34. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron 1996;72:536-543
35. Fiçicioǧlu C, Mikla S, Midilli K, Aydin A, Cam H, Erǧin S. Reduced immune response to hepatitis B vaccine in children with insulin dependent diabetes. Acta Paediatr Jpn 1995;37:687-690 (Pubitemid 26018730)
36. Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini-Moghaddam SM, Zinat NH, Ahmadi F. Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better? Hepat Mon 2011;11:816-820
37. Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus JM. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemodial Int 2005;9:367-375 (Pubitemid 41614648)
38. Li Volti S, Caruso-Nicoletti M, Biazzo F, et al. Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus. Arch Dis Child 1998;78:54-57 (Pubitemid 28177584)
39. Marseglia GL, Scaramuzza A, d'Annunzio G, Comolli G, Gatti M, Lorini R. Successful immune response to a recombinant hepatitis B vaccine in young patients with insulin-dependent diabetes mellitus. Diabet Med 1996;13:630-633 (Pubitemid 26232503)
40. Ocak S, Eskiocak AF. The evaluation of immune responses to hepatitis B vaccination in diabetic and non-diabetic haemodialysis patients and the use of tetanus toxoid. Nephrology (Carlton) 2008;13:487-491
41. Pagani S, Cruciani L, Chianelli M, Procaccini E, Pozzilli P. Thymopentin administration and increase of sero-conversion after B-hepatitis vaccine in diabetic patients. Diabetes Res 1989;12:199-201 (Pubitemid 20144380)
42. Taheri Sh, et al. Response rate to hepatitis B vaccination in patients with chronic renal failure and end-stage-renal-disease: influence of diabetes mellitus. J Res Med Sci 2005;10:384-390 (Pubitemid 41824498)
43. Williams RE, Sena AC, Moorman AC, et al. Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak. Vaccine 2012;30:3147-3150
44. Zitt E, Sprenger-Mähr H, Knoll F, Neyer U, Lhotta K. VitaminDdeficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine 2012;30:931-935
45. Molitch ME, DeFronzo RA, Franz MJ, et al.; American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004;27(Suppl 1):S79-S83
46. Fabrizi F, Dixit V, Martin P. Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006;23:1559-1566 (Pubitemid 43727462)
47. Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 2003;21:3623-3628 (Pubitemid 37338186)
48. Fabrizi F, Dixit V, Messa P, Martin P. Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: a meta-analysis of randomized trials. J Viral Hepat 2011;18:730-737
49. Smith SA, Poland GA; American Diabetes Association. Influenza and pneumococcal immunization in diabetes. Diabetes Care 2004;27(Suppl 1):S111-S113
50. Age-adjusted percentage of obesity for adults with diabetes, United States, 1994-2007. Available from: http://www.cdc.gov/diabetes/statistics/comp/ fig7-obesity.htm. Accessed 6 February 2012
51. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931-2934 (Pubitemid 24000798)
52. Middleman AB, Anding R, Tung C. Effect of needle length when immunizing obese adolescents with hepatitis B vaccine. Pediatrics 2010;125:e508-e512
53. Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 2007;7:1731-1737 (Pubitemid 350157498)
54. Nyström J, Cardell K, Björnsdottir TB, Fryden A, Hultgren C, Sällberg M. Improved cell mediated immune responses after successful re-vaccination of nonresponders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine. Vaccine 2008;26:5967-5972
55. Murdoch DL, Goa K, Figgitt DP. Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs 2003;63:2625-2649 (Pubitemid 37491565)
56. Greub G, Genton B, Safary A, Thoelen S, Frei PC. Comparison of the reactogenicity and immunogenicity of a two injection combined high-dose hepatitis A and hepatitis B vaccine to those of Twinrix. Vaccine 2000;19:1113-1117 (Pubitemid 32008276)
57. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999; 179:489-492 (Pubitemid 29086654)